Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

627.02
+8.071.30%
Volume:580.58K
Turnover:363.16M
Market Cap:66.29B
PE:15.27
High:633.89
Open:628.07
Low:621.11
Close:618.95
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:0.55
T/O Rate:0.56%
Dividend:3.59
Dividend Rate:0.57%
EPS(TTM):41.06
EPS(LYR):41.48
ROE:14.55%
ROA:6.13%
PB:2.11
PE(LYR):15.12

Loading ...

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

GlobeNewswire
·
Yesterday

BRIEF-Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing

Reuters
·
Yesterday

Parabilis Medicines - Intends to Use About $150 Mln of IPO Proceeds to Continue Ongoing Clinical Development of Zolucatetide in Desmoid Tumors

THOMSON REUTERS
·
Yesterday

Parabilis Medicines Inc Says Regeneron Pharmaceuticals Agreed to Buy About $75 Mln of Co's Common Stock in Concurrent Private Placement

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Yesterday

Movement Alert|Regeneron Pharmaceuticals Rises 3.07% in Regular Trading, WHO Ebola Antibody Recommendation and CytomX Partnership Expansion Boost Shares

Market Focus
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise

MT Newswires Live
·
Jun 03

BUZZ-CytomX rises on expanded Regeneron deal with up to $4 billion in milestones

Reuters
·
Jun 03

CytomX expands Regeneron bispecific cancer therapy collaboration, receives $37 million payment

Reuters
·
Jun 03

CytomX Therapeutics - Regeneron Secures Option for 6 Additional Targets; Total Milestones up to About $4 Bln

THOMSON REUTERS
·
Jun 03

CytomX Therapeutics - Eligible for Tiered Global Net Sales Royalties Under Collaboration

THOMSON REUTERS
·
Jun 03

Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

TIPRANKS
·
Jun 02

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 02

FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development

Reuters
·
Jun 01

WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus

Simply Wall St.
·
May 31

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
May 30

Regeneron Advances Phase 3 ROXI-CAT-II Trial, Targeting Safer Cancer-Related Clot Treatment

TIPRANKS
·
May 30

FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development

Reuters
·
May 29